Tags

Type your tag names separated by a space and hit enter

Current scenario of drug development for leishmaniasis.
Indian J Med Res. 2006 Mar; 123(3):399-410.IJ

Abstract

Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the next year, they all suffer from limitations of either cost, specific toxicities or parenteral administration. As part of research to identify better treatments for VL and cutaneous leishmaniasis (CL), alternative and potentially cheaper formulations of amphotericin B, alklyphosphocholines other than miltefosine and improved formulations of paromomycin for CL have been identified. Other drugs or compounds that have demonstrated activity in experimental rodent models of infection include licochalcone derivatives, quinoline derivatives, bisphosphonates and a maesabalide; further chemistry based upon these leads is warranted. The process for discovery and development of new antileishmanials would also benefit from improved models, for example, transfected parasites, and non invasive methods of measuring parasite load in rodent models of infection.

Authors+Show Affiliations

Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland. scroft@dndi.orgNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16778319

Citation

Croft, Simon L., et al. "Current Scenario of Drug Development for Leishmaniasis." The Indian Journal of Medical Research, vol. 123, no. 3, 2006, pp. 399-410.
Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res. 2006;123(3):399-410.
Croft, S. L., Seifert, K., & Yardley, V. (2006). Current scenario of drug development for leishmaniasis. The Indian Journal of Medical Research, 123(3), 399-410.
Croft SL, Seifert K, Yardley V. Current Scenario of Drug Development for Leishmaniasis. Indian J Med Res. 2006;123(3):399-410. PubMed PMID: 16778319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current scenario of drug development for leishmaniasis. AU - Croft,Simon L, AU - Seifert,Karin, AU - Yardley,Vanessa, PY - 2006/6/17/pubmed PY - 2006/8/15/medline PY - 2006/6/17/entrez SP - 399 EP - 410 JF - The Indian journal of medical research JO - Indian J Med Res VL - 123 IS - 3 N2 - Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the next year, they all suffer from limitations of either cost, specific toxicities or parenteral administration. As part of research to identify better treatments for VL and cutaneous leishmaniasis (CL), alternative and potentially cheaper formulations of amphotericin B, alklyphosphocholines other than miltefosine and improved formulations of paromomycin for CL have been identified. Other drugs or compounds that have demonstrated activity in experimental rodent models of infection include licochalcone derivatives, quinoline derivatives, bisphosphonates and a maesabalide; further chemistry based upon these leads is warranted. The process for discovery and development of new antileishmanials would also benefit from improved models, for example, transfected parasites, and non invasive methods of measuring parasite load in rodent models of infection. SN - 0971-5916 UR - https://www.unboundmedicine.com/medline/citation/16778319/Current_scenario_of_drug_development_for_leishmaniasis_ L2 - https://ClinicalTrials.gov/search/term=16778319 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -